Loading
Life sciences · Journal article
Bioactive Materials · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Spinal cord injury (SCI) remains a devastating neurological disorder with few effective therapeutic interventions due to the poor intrinsic regenerative capacity of adult central nervous system neurons. Here, we identified miR-129-5p as a downstream effector of cAMP-response element binding protein (CREB) signaling that promotes axonal growth by suppressing glycogen synthase kinase-3β (GSK3β). Leveraging this regenerative mechanism, we developed a low-intensity focused ultrasound (LIFU)-responsive biomimetic nanoplatform (CM-miR-CNP@PFP) for targeted SCI therapy. The platform comprises miR-129-5p/perfluoropentane (PFP)-loaded cationic lipid nanoparticles (CNPs) coated with hybrid membranes from RVG-engineered human umbilical cord mesenchymal stem cells and macrophages. The biomimetic coating grants superior immune evasion, prolonged circulation, and precise neuronal targeting. Under local LIFU irradiation, CM-miR-CNP@PFP undergoes acoustic droplet vaporization (ADV), a liquid-to-gas phase transition that enhances lesion-site accumulation and cellular delivery of miR-129-5p. In vivo, this ultrasound-responsive therapy significantly attenuated astroglial and fibrotic scar-associated changes, promoted axonal regeneration, and improved motor function. Overall, this biomimetic nanoplatform represents a promising strategy for targeted miRNA delivery and neural regeneration after SCI, with potential for further translational development.